Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $12.57B
- P/E ratio
- —
- EPS
- —
- Volume
- 223,795
- 52-week high
- —
- 52-week low
- —
- Open
- $555.00
- Day high
- $555.00
- Day low
- $533.00
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $958.4M | -$288.28M | -$12.85 |
| 2024 | $180.13M | -$465.89M | -$21.90 |
| 2023 | $0 | -$373.63M | -$19.99 |
| 2022 | $0 | -$295.35M | -$17.23 |
| 2021 | $0 | -$241.85M | -$14.63 |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
- CEO
- William J. Sibold
- Employees
- 915
- Country
- US
- IPO date
- Feb 6, 2007
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Madrigal Pharmaceuticals, Inc.'s stock price today?
- MDGL is trading at $535.69 as of Jul 20, 2026.
- What is Madrigal Pharmaceuticals, Inc.'s market cap?
- Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalization of $12.57B.
- Does Madrigal Pharmaceuticals, Inc. pay a dividend?
- Madrigal Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Madrigal Pharmaceuticals, Inc. in?
- Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector.